Phase 1 N=17 Demodex Blepharitis Treatment Study
Chronic Blepharitis
Primary: Change in the Number of Demodex Mites — -3; -0.4 Mites
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Phase 1 N=22 The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants
Anemia of Prematurity
Primary: Change in Superior Mesenteric Artery Blood Flow Velocity From Pre-to-post Feed in the Anemic and the Transfused States — 2.02; 5.91; 7.66; 14.99 cm/sec — p=0.571
Phase 1 N=45 A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
Healthy
Primary: Drug Liking: Peak Effect (Emax) — 50.9; 60.5; 51.3; 92.8 mm — p=0.0001
Phase 1 N=65 Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
Fungal Infection
Primary: Steady-state Average Concentration (ssCavg) of Posaconazole on Day 8 — 0.0; 88.9; 11.1; 0 Percentage of Participants
Phase 1 N=31 Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Hematopoietic Organs; Disorder
Primary: Number of Lactobacillus Plantarum Bacteremia Infections — 0 Number of infections
Phase 1 N=40 TAK-935 Multiple Rising Dose Study in Healthy Participants
Epilepsy
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 40.0; 0; 16.7; 83.3 percentage of participants
Phase 1 N=4 Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation
Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
Primary: Metabolic Stress
Phase 1 N=2 NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
Sarcoma
Primary: Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03 — 1; 1; 1; 1 participants
Phase 1 N=297 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Cancer · Solid Tumor
Primary: Number of Participants Experiencing Adverse Events (AEs) — 32; 58; 33; 39 Participants
Phase 1 N=12 Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
Rett Syndrome
Primary: Adverse Events — 4; 4; 2; 17 Adverse events
Phase 1 N=6 A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Advanced Solid Tumors · Lymphomas
Primary: Maximum Plasma Concentration (Cmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib — 485.2; 426.8 ng/mL
Phase 1 N=54 A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Schizophrenia
Primary: Physical Examination Shift Table — 1; 1; 0; 0 Participants abnormal at end of study
Phase 1 N=145 A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
Psoriasis
Primary: Pharmacokinetic Parameters for the Maximum Amount of Observed Brodalumab Concentration for Treatment A and Treatment B. — 13.8; 14.8 milligrams per milliliter
Phase 1 N=45 A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)
Hodgkin Disease · Lymphoma, Non-Hodgkin · Neoplasms
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 0 and Cycle 1 Based on National Cancer Institute Common Terminology Criteria for…